The association between GRS and nonaggressive classification was not significant upon the removal of 51 variants that have also been reported to associate with PSA expression from the GRS, supporting previous observations that accounting for baseline PSA when incorporating information from a GRS into decisions on whether or not to biopsy may have the potential to reduce the likelihood of overdiagnosis of individuals with lower-risk tumours [30]. This evidence concerns the gene KLK3 and neoplasm.